Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study

Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, Kiecker F, Loquai C, Debus D, Gutzmer R (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 4-4

Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

DOI: 10.1016/j.annonc.2022.07.954

Authors with CRIS profile

Carola Berking Lehrstuhl für Haut- und Geschlechtskrankheiten

Involved external institutions

Universitätsklinikum Essen DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Novartis AG CH Switzerland (CH) Charité - Universitätsmedizin Berlin DE Germany (DE) Elbe Kliniken Stade-Buxtehude DE Germany (DE) Dermatologie am Schlachtensee DE Germany (DE) Klinikum Bremen-Ost DE Germany (DE) Klinikum Nürnberg DE Germany (DE) Johannes Wesling Klinikum Minden DE Germany (DE)

How to cite

APA:

Berking, C., Livingstone, E., Weichenthal, M., Leiter-Stoeppke, U., Remy, J., Eigentler, T.,... Gutzmer, R. (2022). Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 4-4). HOBOKEN: WILEY.

MLA:

Berking, Carola, et al. "Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2022. 4-4.

BibTeX: Download